Charles River Laboratories International

Charles River Laboratories International

Research models, and outsourced preclinical services for the accelerated r&d of drugs.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
*
N/A

N/A

Post IPO Debt
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth21 %12 %4 %(2 %)(4 %)2 %3 %
EBITDA0000000000000000000000000000
% EBITDA margin23 %25 %25 %20 %24 %25 %26 %
Profit0000000000000000000000000000
% profit margin11 %12 %11 %1 %6 %7 %8 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article, Equity research estimates

More about Charles River Laboratories International
Made with AI
Edit

Charles River Laboratories, accessible via criver.com, is a pioneering company in the life sciences sector, dedicated to advancing the discovery, development, and safe manufacture of novel drugs and therapies. With a legacy of 70 years, Charles River has been at the forefront of innovation, particularly in the responsible advancement of alternative methods in animal research, focusing on replacement, reduction, and refinement.

The company operates in the biopharmaceutical market, serving a diverse clientele that includes pharmaceutical and biotechnology companies, government agencies, and academic institutions. Charles River offers a broad range of services, from basic research to comprehensive solutions for antibody discovery and cell therapy manufacturing. Their services are designed to accelerate the development of biopharmaceuticals from concept to cure, ensuring compliance with current Good Manufacturing Practices (CGMP).

Charles River's business model revolves around providing flexible and scalable testing platforms and manufacturing services. These platforms can be deployed at client facilities, satellite labs, or within Charles River's own extensive network of over 100 facilities in more than 20 countries. This flexibility allows clients to expedite their research and development processes efficiently.

Revenue generation for Charles River comes from offering specialized contract research and manufacturing services. These services include biologics contract manufacturing, antibody discovery, and cell therapy manufacturing, all tailored to meet the unique needs of their clients. Additionally, the company invests heavily in environmental, social, and governance (ESG) strategies, aiming to achieve 100% renewable electricity globally by 2030, which underscores their commitment to sustainability.

In summary, Charles River Laboratories is a key player in the life sciences industry, providing essential services that support the development of new drugs and therapies, with a strong emphasis on innovation, flexibility, and sustainability.

Keywords: biopharmaceuticals, antibody discovery, cell therapy, CGMP compliance, contract manufacturing, life sciences, drug development, ESG strategies, renewable electricity, supply chain integration.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo
Investments analysisEdit

Investments by Charles River Laboratories International

Edit
Chantest
ACQUISITION by Charles River Laboratories International Oct 2014
Molecular Therapeutics
ACQUISITION by Charles River Laboratories International Sep 2008
Systems Pathology Company
ACQUISITION by Charles River Laboratories International Aug 2009
Aspect Medical Systems
ACQUISITION by Covidien Sep 2009
Caprotec Bioanalytics
ACQUISITION by Charles River Laboratories International Jul 2017
Accugenix
ACQUISITION by Charles River Laboratories International Aug 2012
Citoxlab
ACQUISITION by Charles River Laboratories International Feb 2019
Northwest Kinetics
ACQUISITION by Charles River Laboratories International Oct 2006
View 24 more